Related Experiment Videos
[Effect of meproscillarin on left ventricular hemodynamics (author's transl)]
Arzneimittel-Forschung
|January 1, 1978
Summary
Meproscillarin, a cardiac glycoside, improved left ventricular performance in patients with coronary artery disease by reducing end-diastolic pressure and increasing pressure rise rate. Heart rate remained stable during the study.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Context:
- Coronary artery disease (CAD) affects myocardial function.
- Cardiac glycosides are known to influence cardiac contractility.
- Assessing novel therapeutic agents for heart conditions is crucial.
Purpose:
- To evaluate the acute hemodynamic effects of meproscillarin in patients with CAD.
- To investigate the impact of meproscillarin on left ventricular pressure and its rate of change.
- To determine if meproscillarin affects heart rate in patients with coronary artery disease.
Summary:
- A single intravenous bolus injection of meproscillarin was administered to 10 patients with confirmed coronary artery disease.
- Meproscillarin significantly decreased left ventricular end-diastolic pressure.
- Concurrently, a notable increase in the maximum rate of pressure rise (dp/dtmax) and overall left ventricular pressure (LVP) was observed.
Impact:
- Meproscillarin demonstrates potential as a therapeutic agent for improving left ventricular function in CAD patients.
- The observed hemodynamic changes suggest a positive inotropic effect without significant chronotropic effects.
- Further research may explore long-term efficacy and safety of meproscillarin in cardiovascular conditions.